Four federal developments in psychedelic policy this week.

The Veterans Administration launched a five-site psilocybin trial for veterans with treatment-resistant depression. The drug it runs on belongs to Compass Pathways, which donated it and is preparing an approval application.

Federal research infrastructure generating data that supports a private asset is worth considering.

The Senate voted to delay the federal hemp THC ban by one month.

FDA finalized its guidance on how psychedelic clinical trials should be designed. A FDA hearing is scheduled for September 14.

Psychedelic Policy Briefing August 9 2026